On May 20, 2022, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab). This approval specifically relates to the drug's efficacy, indicating an expansion or modification of its therapeutic uses based on new clinical data.
Background
Keytruda (pembrolizumab) is an established oncology therapeutic. Supplemental approvals for efficacy, such as this one, are granted when new clinical evidence demonstrates additional benefits or expands the eligible patient population for an already approved drug. These approvals are crucial for broadening treatment options for patients and for optimizing the use of existing therapies.
What this means
This supplemental FDA approval for Keytruda (pembrolizumab) signifies that new clinical data has supported an expansion or refinement of its approved indications related to its effectiveness. While the specific details of the new indication, such as a new cancer type, a different line of therapy, or a new patient subgroup, are not explicitly detailed in this announcement, such approvals typically allow the drug to be used in a broader context. Clinicians and researchers should refer to the updated prescribing information provided by the sponsor, Merck Sharp Dohme, to understand the precise details of this expanded approval and its implications for patient care.
Source
The information regarding this supplemental FDA approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125514 S-123 for Keytruda (pembrolizumab) was granted on May 20, 2022, and is publicly accessible on accessdata.fda.gov.